ClinicalTrials.gg
RecruitingNCT06622317Updated Apr 17, 2025

Abdominal Aortic Junction Tourniquet (AAJT-S) for Non-compressible Torso Haemorrhage

An observational study in Exanguination, NCTH and Polytrauma, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by Medical University of Graz · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

This study seeks to evaluate the feasibility of a Abdominal Aortic Balloon Occlusion of the Aorta (AAJT-S) in exanguinating trauma patients with non-compressible truncal haemorrhage in the emergency room and the pre-hospital setting.

Read the detailed description

The study is designed as a prospective observational study to accomapany the impementation of this device in clinical routine. However, the device has already been used in the emergency room and AAJT-S application is no study specific intervention.

02

Conditions studied

  • Exanguination
  • NCTH
  • Polytrauma

Browse trials for

Keywords

  • NCTH
  • aortic occlusion
  • exanguniation
03

In context

Multiple Trauma

139 studies on the registry are indexed under Multiple Trauma; 32 are open to participants now.

This study's planned enrollment of 10 is below the median of 200 across 84 observational studies indexed under Multiple Trauma.

Browse Multiple Trauma studies →

Lead sponsor

Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

all patients meeting the eligibility criteria that are being transported to the rescucitation room of the Medical University of Graz

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged, or believed to be aged, 18 years or above,
  • confirmed or suspected life-threatening lower body trauma (i.e. signs of inadequate perfusion of tissues, tachycardia, hypotension, suspected blood loss)
  • is thought to benefit from trauma resuscitation with AAJT-S or REBOA zone III

Exclusion criteria

Exclusion Criteria:

  • suspected additional bleeding source proximal to the umbilicus, or
  • known or suspected pregnancy at presentation, or
  • known abdominal aortic aneurysm
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. effective placement of the device

    cessation of bloodflow distal to the device

    Time frame: 1 hour

Secondary outcomes

  1. 30-day mortality

    in-hospital

    Time frame: 30 days

  2. Complications

    Occurrence of complications of device application

    Time frame: 90 days

  3. Heart rate

    Improvement (reduction) in beats/minute

    Time frame: 1 hour

  4. Base excess

    Improvement (reduction) in mmol/l

    Time frame: 1hour

  5. Blood pressure (systolic and diastolic)

    Improvement in mmHg

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06622317
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Nov 1, 2024
Primary completion
Sep 17, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 17, 2025

Study contacts

Gabriel Honnef, MD, PhD
Contact
gabriel.honnef@medunigraz.at
004331638581283

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion